Cystic Fibrosis Medication for Gating Mutations

Trial Objective

Cystic Fibrosis Medication for Gating MutationsThis study is evaluating the safety and effectiveness of a new investigational medication called VX-561, an altered form of KALYDECO® (generic: ivacaftor), compared to the original ivacaftor. Researchers believe VX-561 has a longer action time in the blood and may be more stable in the body than ivacaftor. They are testing four different doses of VX-561 to see which dose is as effective as ivacaftor when taken once daily.

Enrollment

This trial is active and currently recruiting.

Who Can Participate

Adults with cystic fibrosis (CF) who are currently taking KAYLDECO (ivacaftor) and have CF gating mutations.

Age: 18+    Gender: Any Gender


Estimated Time Commitment

8 visits up to 20 weeks



Compensation

Provided

Trial Contact

For more information, contact:

Alexandra Wilson

Alexandra Wilson
303.270.2321

Request More Information

Trial Location

National Jewish Main Campus, Denver, CO

Trial Sponsors

Vertex Pharmaceuticals Incorporated

Principal Investigators


Request More Information


*
*
*
*